ALBERTO AZOUBEL ANTUNES
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Cirurgia, Faculdade de Medicina - Docente
LIM/55 - Laboratório de Urologia, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/55 - Laboratório de Urologia, Hospital das Clínicas, Faculdade de Medicina - Líder
16 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 16
- Prostate biopsy in patients with long-term use of indwelling bladder catheter: What is the rationale?(2012) ANTUNES, Alberto A.; BARBOSA, Joao Arthur B. A.; REIS, Sabrina T.; GUARIERO, Mary S.; FUKUSHIMA, Julia T.; DALL'OGLIO, Marcos F.; FREIRE, Geraldo de C.; LUCON, Antonio M.; LEITE, Katia R.; SROUGI, MiguelObjective: Acute urinary retention (AUR) is expected to occur in 2% to 39% men with benign prostatic hyperplasia. To date, no study has elucidated the effect of long-term use of indwelling bladder catheter on serum prostate specific antigen (PSA) levels and on the incidence of prostate cancer (CaP). The aim of the present study is to analyze the incidence of CaP in patients with long-term use of indwelling bladder catheter and determine some practice patterns on this issue. Materials and methods: The study comprised a retrospective analysis of data from 1,651 patients who had undergone transrectal ultrasound (TRUS)-guided prostate biopsy from July 2004 to June 2009. Among these patients, 198 (12%) were using an indwelling bladder catheter during the biopsy for at least 1 month. The incidence of CaP was recorded according to total PSA levels. Other variables such patient age, free/total PSA rate, PSA density, prostate volume, and duration of catheter use was also analyzed. Men with a digital rectal examination suspicious for cancer were not considered for analysis. Results: Median patient age was 71 years (37 to 89 years). Overall, 25% of patients presented a CaP diagnosis. CaP incidence according to the PSA levels was 0%, 18.9%, 24.5%, and 40.6% for patients with PSA <= 4.0, 4.1-10.0, 10.1-20.0, and >20.0 ng/ml, respectively. When prostate volume was analyzed together, we demonstrated that only 1 (2.4%) patient with PSA below 10.0 ng/ml and prostate volume >60 g had CaP. Median total PSA, PSA density, and prostate volume were statistically different between patients with and without CaP. Conclusions: Prostate biopsy should not be indicated for all patients with diagnosis of BPH and AUR who present an elevated PSA level. Patients with PSA below 10.0 ng/ml, and prostate volume >60 g should only undergo biopsy in selected cases. Patients with PSA >20.0 ng/ml and a prostate volume <= 60 g are at higher risk of CaP diagnosis.
- GREB1 tissue expression is associated with organ-confined prostate cancer(2012) ANTUNES, Alberto A.; LEITE, Katia R.; REIS, Sabrina T.; SOUSA-CANAVEZ, Juliana M.; CAMARA-LOPES, Luiz H.; DALL'OGLIO, Marcos F.; SROUGI, MiguelObjective: By reason of its heterogeneous behavior, it is difficult to determine the prognosis of many prostate cancer cases. Patients with the same clinicopathologic conditions may present varying clinical findings and rates of progression. We determined the role of new genes as potential molecular markers for prostate cancer prognosis. Materials and methods: We performed a microarray analysis of two pools of patients with prostate cancer divided according to their clinicopathologic characteristics. After that, we validated these results by testing the genes with most different expressions between the two pools using the quantitative real time polymerase chain reaction method. We analyzed gene expression in 33 patients with localized prostate cancer according to prostate specific antigen (PSA), pathologic stage, Gleason score, and biochemical recurrence. For statistical analysis we used the Mann-Whitney Test. Results: The microarray analysis revealed that 4,147 genes presented a different expression between the two pools. Among them, 3 genes, TMEFF2, GREB1, and THIL,, were at least 13-times overexpressed, and 1 gene, IGH3, which was at least 5times under-expressed in pool 1 (good prognosis) compared with pool 2 (bad prognosis), were selected for analysis. After the validation tests, GREB1 was significantly more overexpressed among patients with stage T2 compared with T3 (P = 0.020). The expressions of other 3 genes did not present significant differences according to the clinicopatholoOcal variables. Conclusions: Tissue expression of GREB1 is associated with organ-confined prostate cancer and may constitute a gene associated with a favorable prognosis.
conferenceObject EXPRESSION PROFILE OF CD105 IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA (BPH): A NEW ANGIOGENIC MARKER(2013) BIOLO, Karlo; KIRIHARA, Ricardo; REIS, Sabrina T.; VIANA, Nayara I.; SAJOVIC, Paulo; ARAUJO, Luiz Henrique; LEITE, Katia R.; SROUGI, Miguel; ANTUNES, Alberto A.conferenceObject ROLE OF MICRORNAS IN REGULATING TISSUE INFLAMMATION IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA: PRELIMINARY RESULTS(2013) OLIVEIRA, Fabio; SAGAE, Vitor; REIS, Sabrina T.; VIANA, Nayara I.; LEITE, Katia R.; SROUGI, Miguel; ANTUNES, Alberto A.- The Obstructed Bladder: Expression of Collagen, Matrix Metalloproteinases, Muscarinic Receptors, and Angiogenic and Neurotrophic Factors in Patients With Benign Prostatic Hyperplasia(2017) BARBOSA, Joao Arthur Brunhara Alves; REIS, Sabrina T.; NUNES, Marco; FERREIRA, Yuri A.; LEITE, Katia R.; NAHAS, William C.; SROUGI, Miguel; ANTUNES, Alberto A.OBJECTIVE To evaluate the gene expression of collagen, matrix metalloproteinases (MMPs) and inhibitors, cholinergic muscarinic receptors (CHRMs), and angiogenic and nerve growth factors (NGFs) in the bladder of patients with bladder outlet obstruction caused by benign prostatic hyperplasia (BPH). METHODS We analyzed bladder specimens from 43 patients with obstructive BPH undergoing transurethral resection of the prostate as compared to 10 age-matched controls with an International Prostatic Symptom Score of <8 and a prostate volume of < 30 g. A bladder biopsy was performed for relative gene expression analysis with quantitative real-time polymerase chain reaction of collagens I and III, MMP-1, MMP-2, and MMP-9; tissue inhibitors of metalloproteinases (TIMPs) TIMP1, TIMP-2, and reversion-inducing cysteine-rich protein with kazal motifs (RECK); CHRM2 and CHRM3; VEGF and CD105; and NGF and nerve growth factor receptor (NGFr). RESULTS Patients with bladder outlet obstruction presented a statistically significant overexpression of collagens I and III, VEGF, CHRM2, and CHRM3. CD105, MMP-9, and TIMP-1 were underexpressed. Expressions of NGF, NGFr, MMP-1, MMP-2, TIMP-2, and RECK were heterogeneous. CHRM2 and CHRM3 were overexpressed in patients with persistent detrusor overactivity. Smokers presented an upregulation of NGFr and VEGF; dyslipidemic patients had an overexpression of NGFr. CONCLUSION Bladder upregulation of collagens I and III on transcriptional level appears to be relevant in BPH. Muscarinic receptors CHRM2 and CHRM3 are also overexpressed, more so in patients with persistent detrusor overactivity. Upregulation of VEGF and NGFr, particularly in subjects with risk factors for atherosclerosis, reinforces the role of ischemia in BPH-induced modifications of the bladder. (C) 2017 Elsevier Inc.
- Prima-1 induces apoptosis in bladder cancer cell lines by activating p53(2013) PIANTINO, Camila B.; REIS, Sabrina T.; VIANA, Nayara I.; SILVA, Iran A.; MORAIS, Denis R.; ANTUNES, Alberto A.; DIP, Nelson; SROUGI, Miguel; LEITE, Katia R.OBJECTIVES: Bladder cancer represents 3% of all carcinomas in the Brazilian population and ranks second in incidence among urological tumors, after prostate cancer. The loss of p53 function is the main genetic alteration related to the development of high-grade muscle-invasive disease. Prima-1 is a small molecule that restores tumor suppressor function to mutant p53 and induces cancer cell death in various cancer types. Our aim was to investigate the ability of Prima-1 to induce apoptosis after DNA damage in bladder cancer cell lines. METHOD: The therapeutic effect of Prima-1 was studied in two bladder cancer cell lines: T24, which is characterized by a p53 mutation, and RT4, which is the wild-type for the p53 gene. Morphological features of apoptosis induced by p53, including mitochondrial membrane potential changes and the expression of thirteen genes involved in apoptosis, were assessed by microscopic observation and quantitative real-time PCR (qRT-PCR). RESULTS: Prima-1 was able to reactivate p53 function in the T24 (p53 mt) bladder cancer cell line and promote apoptosis via the induction of Bax and Puma expression, activation of the caspase cascade and disruption of the mitochondrial membrane in a BAK-independent manner. CONCLUSION: Prima-1 is able to restore the transcriptional activity of p53. Experimental studies in vivo may be conducted to test this molecule as a new therapeutic agent for urothelial carcinomas of the bladder, which characteristically harbor p53 mutations.
conferenceObject ROLE OF PHYSICAL ACTIVITY IN THE PREVENTION OF BPH THROUGH INHIBITION OF PROSTATIC IGF1/AKT PROLIFERATIVE AXIS: AN EXPERIMENTAL STUDY IN RATS.(2015) FONSECA, Fernando Froes; OLIVEIRA, Andre M.; REIS, Sabrina T.; LEITE, Katia R.; NAHAS, William C.; SROUGI, Miguel; ANTUNES, Alberto A.- PGC and PSMA in prostate cancer diagnosis: tissue analysis from biopsy samples(2013) ANTUNES, Alberto A.; REIS, Sabrina T.; LEITE, Katia R.; REAL, Danilo M.; SOUSA-CANAVEZ, Juliana M.; CAMARA-LOPES, Luiz H.; DALL'OGLIO, Marcos F.; SROUGI, MiguelPurpose: The discovery of new diagnostic tools for the diagnosis of prostate cancer (PCa) has become an important field of research. In this study, we analyzed the diagnostic value of the expression of the pepsinogen C (PGC) and prostate-specific membrane antigen (PSMA) genes in tissue samples obtained from prostate biopsies. Materials and Methods: This study was comprised of 51 consecutive patients who underwent transrectal ultrasound (TRUS)-guided prostate biopsies between January 2010 and March 2010. The biopsies were performed with 12 cores, and an additional core was randomly retrieved from the peripheral zone from each patient for study purposes. The expression of the PGC and PSMA genes was analyzed from the cDNA from the samples via the qRT-PCR technology. The expression patterns of patients with PCa were compared with those of patients without a PCa diagnosis. Results: PSMA was overexpressed in only 43.4% of PCa cases, and PGC was overexpressed in 72.7% of cases. The median expression of PSMA was 1.5 times (0.1 to 43.9) and the median PGC expression was 8.7 times (0.1 to 50.0) the expression observed in prostatic tissue from TRUS-guided biopsies of normal patients. Analysis of patients with high-risk PCa indicated that PGC was overexpressed in 71.4% of cases (with a median expression of 10.6 times), and PSMA was overexpressed in only 35.7% of cases (with a median expression of 4.5 times). Among patients with low-risk PCa, PGC was also overexpressed in 71.4% of cases (with a median expression of 5.9 times), and PSMA was overexpressed in only 42.8% of cases (with a median expression of 2.5 times). Conclusions: PGC gene expression is significantly higher in prostatic tissue in men affected by PCa when compared to normal prostates. Further analyses are necessary to confirm our results.
conferenceObject THE ROLE OF ANGIOGENIC AND NEUROGENIC MARKERS ON DETRUSOR OVERACTIVITY IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA AND BLADDER OUTLET OBSTRUCTION(2013) NUNES, Marco A.; SAKUMA, Mayara; BRUNHARA, Joao A.; REIS, Sabrina T.; VIANA, Nayara I.; LEITE, Katia R.; SROUGI, Miguel; ANTUNES, Alberto A.- Re: PGC and PSMA in prostate cancer diagnosis: tissue analysis from biopsy samples(2014) ANTUNES, Alberto A.; REIS, Sabrina T.; LEITE, Katia R.; REAL, Danilo M.; SOUSA-CANAVEZ, Juliana M.; CAMARA-LOPES, Luiz H.; DALL'OGLIO, Marcos F.; SROUGI, Miguel